109 related articles for article (PubMed ID: 38775200)
21. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
22. EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.
Yasir M; Park J; Chun W
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894854
[TBL] [Abstract][Full Text] [Related]
23. Next steps in preventing Ewing sarcoma progression.
Knott MM; Dallmayer M; Grünewald TG
Future Oncol; 2016 Jan; 12(1):1-4. PubMed ID: 26615856
[No Abstract] [Full Text] [Related]
24. Ewing sarcoma with myxoid stroma: Case report of an unusual histological variant.
Alexiev BA; Obeidin F; Jennings LJ
Pathol Res Pract; 2019 Dec; 215(12):152665. PubMed ID: 31585812
[TBL] [Abstract][Full Text] [Related]
25. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
26. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
27. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
28. [Malignant round cell tumors : The Ewing sarcoma and beyond].
Haybaeck J; Roessner A
Pathologe; 2020 Mar; 41(2):116-122. PubMed ID: 32060684
[TBL] [Abstract][Full Text] [Related]
29. GD2-directed CAR-T cells in combination with HGF-targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma.
Charan M; Dravid P; Cam M; Audino A; Gross AC; Arnold MA; Roberts RD; Cripe TP; Pertsemlidis A; Houghton PJ; Cam H
Int J Cancer; 2020 Jun; 146(11):3184-3195. PubMed ID: 31621900
[TBL] [Abstract][Full Text] [Related]
30. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
Uren A; Toretsky JA
Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
[TBL] [Abstract][Full Text] [Related]
31. Establishment and characterization of a novel patient-derived Ewing sarcoma cell line, NCC-ES2-C1.
Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Akiyama T; Nakagawa R; Kamio S; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2022 Jul; 35(4):1262-1269. PubMed ID: 35441357
[TBL] [Abstract][Full Text] [Related]
32. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth.
Surdez D; Benetkiewicz M; Perrin V; Han ZY; Pierron G; Ballet S; Lamoureux F; Rédini F; Decouvelaere AV; Daudigeos-Dubus E; Geoerger B; de Pinieux G; Delattre O; Tirode F
Cancer Res; 2012 Sep; 72(17):4494-503. PubMed ID: 22930730
[TBL] [Abstract][Full Text] [Related]
33. Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes.
Sand LG; Szuhai K; Hogendoorn PC
Int J Mol Sci; 2015 Jul; 16(7):16176-215. PubMed ID: 26193259
[TBL] [Abstract][Full Text] [Related]
34. STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma.
Surdez D; Zaidi S; Grossetête S; Laud-Duval K; Ferre AS; Mous L; Vourc'h T; Tirode F; Pierron G; Raynal V; Baulande S; Brunet E; Hill V; Delattre O
Cancer Cell; 2021 Jun; 39(6):810-826.e9. PubMed ID: 33930311
[TBL] [Abstract][Full Text] [Related]
35. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
Kovar H
Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
[TBL] [Abstract][Full Text] [Related]
36. Integrated multimodal genetic testing of Ewing sarcoma--a single-institution experience.
Warren M; Weindel M; Ringrose J; Venable C; Reyes A; Terashima K; Rao P; Chintagumpala M; Hicks MJ; Lopez-Terrada D; Lu XY
Hum Pathol; 2013 Oct; 44(10):2010-9. PubMed ID: 23706910
[TBL] [Abstract][Full Text] [Related]
37. Ewing sarcoma treatment: a gene therapy approach.
Tsibulnikov S; Fayzullina D; Karlina I; Schroeder BA; Karpova O; Timashev P; Ulasov I
Cancer Gene Ther; 2023 Aug; 30(8):1066-1071. PubMed ID: 37037906
[TBL] [Abstract][Full Text] [Related]
38. An
Bissonnette C; Shilo K; Liebner D; Rogers A; Pollock RE; Iwenofu OH
Int J Surg Pathol; 2021 Feb; 29(1):109-116. PubMed ID: 32506986
[TBL] [Abstract][Full Text] [Related]
39. An inducible ectopic expression system of EWSR1-FLI1 as a tool for understanding Ewing sarcoma oncogenesis.
García-Domínguez DJ; Hontecillas-Prieto L; León EA; Sánchez-Molina S; Rodríguez-Núñez P; Morón FJ; Hajji N; Mackintosh C; de Álava E
PLoS One; 2020; 15(6):e0234243. PubMed ID: 32502203
[TBL] [Abstract][Full Text] [Related]
40. EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma.
Charville GW; Wang WL; Ingram DR; Roy A; Thomas D; Patel RM; Hornick JL; van de Rijn M; Lazar AJ
Mod Pathol; 2017 Sep; 30(9):1312-1320. PubMed ID: 28643791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
